Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Oxametacin is a non-steroidal anti-inflammatory drug (NSAID) belonging to the benzoylindole class of organic compounds. It exhibits analgesic (pain-relieving), antipyretic (fever-reducing), and anti-inflammatory properties. Its mechanism of action is primarily through inhibition of cyclooxygenase enzymes involved in prostaglandin synthesis. Oxametacin has been used for the treatment of pain and inflammation associated with musculoskeletal disorders and acute gout attacks. Additionally, it has shown inhibitory activity toward histone deacetylases in preclinical studies and demonstrated selectivity against leukemic cell lines over solid tumor cell lines[2][3][4][5]. The adverse effect profile is similar to that of indometacin; gastrointestinal and nervous system side effects are common[8].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on oxametacin.